STAT Plus: Can Novartis charge $4 million for a one-time drug?
RUBY WALLAU FOR STAT
The drug maker believes its new gene therapy is worth more than $4 million, and has some data to back that up. But would that price be politically viable?
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario